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INTRODUCTION 
Fibromyalgia (FM) is a highly disabling syndrome affecting 2.9% of the European population 
[3], mainly women in the fourth decade of life, with a female:male ratio of 21:1 [33]. 
Fibromyalgia is defined by a low pain threshold and a permanent state of pain, 
accompanied by a constellation of symptoms, such as fatigue, sleep disturbances and 
cognitive impairment, among others. In the absence of suitable diagnostic tests, FM 
diagnosis is established by the presence of symptoms for at least three months and the 
exclusion of somatic diseases [43; 44]. 
The mechanisms explaining this chronic pain remain unclear. The most established 
hypothesis underlying FM etiopathogenesis is the existence of a dysfunction in pain 
processing. FM patients have been shown to present structural differences in the brain [13; 
19]. Furthermore, there are several evidences of central sensitization at various levels in 
the nervous system [11], as well as neurochemical imbalances in the central nervous 
system leading to a “central amplification” of pain perception [14; 45]. 
The response to painful stimuli and the FM phenotype have both a genetic component. FM 
shows family aggregation [4; 5] and higher concordance in monozygotic than dizygotic 
twins (0.29 vs. 0.16) [18], while the response to painful stimuli has  an estimated heritability 
of 22% to 55% [28]. However, the exploration of the genetic contribution to pain response 
and chronic pain states is, so far, scarce [27]. 
Genetic studies performed so far in FM have not been able to establish a clear genetic 
association.  Most of them have been candidate gene studies, focused on genes related to 
HLA and neurotransmitters [17; 21; 47]. So far, two studies have attempted to explore the 
genetic contribution to FM in a genome-wide manner. One of them analyzed over 3200 
SNPs in 350 genes implicated in pain transmission, inflammatory responses, and in 
influencing mood and affective states associated with chronic pain conditions, in 496 FM 
cases and 348 controls. However, the strongest associations did not replicate in 
independent cohorts [35]. The other one was a linkage scan evaluating 341 markers in 206 
affected sibling pairs. They detected a signal in chromosome 17 but no replication analysis 
was performed [1]. Another recent GWAS study investigating genetic factors involved in 
chronic widespread pain [30] identified a region of association in chromosome 5, near CCT5 
and FAM173B. These two genes also showed a higher RNA-expression in mouse models of 
inflammatory pain.   
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The aim of this study was to elucidate genetic susceptibility factors for fibromyalgia. We 
addressed this objective through two main approaches: a genome-wide association study 
(GWAS) and the evaluation of copy number variants (CNVs), using genotyping data and 
array comparative genomic hybridization experiments (aCGH). These analyses were 
performed on a large and very well characterized cohort of FM patients. 
 
MATERIALS AND METHODS 
Samples 
Fibromyalgia Units of five Spanish Hospitals participated in the collection of samples. An 
initial set of 313 female samples (FM_discovery), characterized by having low levels of 
psychiatric comorbidities and being the best fitting the FM diagnosis, was collected at the 
beginning of the study, and collection continued until an additional set of 1088 female 
patients (FM_replication) was achieved (total female FM cohort = 1401). All patients 
fulfilled the 1990’s American College of Rheumatology (ACR) criteria for fibromyalgia and 
were selected by the rheumatologists of the units participating in the study. Patients were 
then evaluated by another set of physicians trained in the assessment of FM patients. They 
all passed the same questionnaires and physical examination. For a detailed description of 
the cohort, see Docampo et al,. 2013 [9]. All samples were Spanish of Caucasian origin and 
had signed informed consent before enrolment. The ethics committees at all recruitment 
centers approved the project. 
We recently performed cluster analysis on the whole cohort of patients, and found that 
they could be classified into three empirical subgroups, which we then labeled: “FM with 
low levels of comorbidities and symptomatology” (cluster 1), “FM with high levels of both 
symptomatology and comorbidities” (cluster 2), and “FM with high symptomatology but 
low levels of comorbidities” (cluster 3) [9]. A brief summary of the process is provided in 
the supplementary methods.  
Three different control cohorts were used for this study: a cohort of 220 female Spanish 
samples (ECHRS) from the GABRIEL consortium (http://www.cng.fr/gabriel/index.html) was 
used in the GWAS analysis (con_ECHRS). In the GWAS replication studies, we genotyped a 
cohort of  535 female control samples (con_SAL), corresponding to subjects with low levels 
of pain and fatigue (as assessed by a questionnaire) provided by the National DNA Bank of 
Salamanca, and a set of 142 female Spanish blood donor samples (con_VH). For the CNV 
analysis, only the con_SAL set of control samples was used.  
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A flowchart representing the different cohorts and the analysis in which they were used is 
provided in the supplementary material (supplementary figure 1). 
Whole genome association study 
Genotyping 
FM female cases (313 samples, FM_discovery), selected by clinicians for having low levels of 
psychiatric comorbidities and being the best fitting the FM diagnosis, were genotyped with 
Illumina 1M-Duo chip. Genotyping was performed in CeGen (Barcelona Node), following 
the manufacturer’s protocol. 
Data from 220 general Spanish population samples (GABRIEL consortium 
http://www.cng.fr/gabriel/index.html) genotyped with Illumina 610-quad chip was used as 
control dataset (con_ECHRS). 
Quality control 
Quality control (QC) was performed with PLINK [32] (Supplementary methods). 
Allelic association 
Allelic association analysis was performed with PLINK (5% of significance level). QQ plots 
were performed with the WGAviewer software [12], and Manhattan plot and linkage 
disequilibrium (LD) evaluation with Haploview software [2]. 
Power analysis was performed with Quanto (http://hydra.usc.edu/gxe/), showing that for 
SNPs with MAF≥0.05, and given our sample size, we had over 80% power to detect 
associations with OR≥2.0 but it showed much lower power to detect associations with 
smaller OR (1.2) (supplementary methods). 
Imputation 
For GWAS regions showing positive signals, we performed imputation in a window span of 
100kb with Impute v2 (http://mathgen.stats.ox.ac.uk/impute/impute_v2.html) 
(Supplementary methods).  
SNPs annotation and Pathway analysis 
SNPs showing strongest association were annotated with WGAViewer [12]. The relation to 
disease of the SNPs and their genomic regions was evaluated with the Decipher database 
(http://decipher.sanger.ac.uk/). These SNPs were also analyzed with Ingenuity Systems 
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Pathway analysis (IPA) software (http://www.ingenuity.com/) and GeneSet analysis Toolkit 
v2 (http://bioinfo.vanderbilt.edu/webgestalt/). The function of associated SNPs was 
evaluated with Genevar (http://www.sanger.ac.uk/resources/software/genevar/) (1 MB 
window centred in the transcription start site of the gene, Spearman Rank Correlation (p 
<0.001)), Puppasuite (http://pupasuite.bioinfo.cipf.es/), and the Regulome database 
(http://www.regulomedb.org/). 
Replication 
Twenty-one SNPs showing strongest association values were genotyped in a replication set 
from our cohort, consisting in 952 female FM cases (FM_replication) and 644 female 
controls (529 from con_SAL + 115 from con_VH). These SNPs were prioritized based on 
their p-values, the presence of association peaks (clustering of SNPs with strong 
associations in a genomic region), their function (only including SNPs located in genes or 
gene regions recognizedby UCSC genome browser and WGA viewer software), and pathway 
analysis results, focusing on genes from the highlighted neurological disease pathway. 
Genotyping was performed by Kbiosciences (KASPar®). As quality control, duplicates (two 
HapMap samples in each plate) and negative controls where included. SNPs not fulfilling 
HWE, with a MAF <5% or a low genotyping rate (<95%), as well as samples with low 
genotyping rate (<95%), were excluded from the analysis. This resulted in the exclusion of 
one SNP and 55 samples (12 cases and 43 controls). Association analysis was performed 
with SNPassoc R package. 
 
CNV analysis 
CNVs were assessed by aCGH. Experiments were performed with the Agilent® 400K using a 
pooling strategy to dilute common CNV polymorphisms due to inter-individual variability 
and highlight those common variants with a different frequency between cases and 
controls [8]. From the FM_discovery set, three pools of FM samples were designed, two 
with 20 FM cases each (FM_1 and FM_2) and one with 30 cases (FM_3). All the samples 
included in the pools had a family history of FM, and low levels of psychiatric comorbidities, 
and were grouped based on characteristics such as absence (FM1) or presence (FM2) of 
Chronic Fatigue Syndrome, or early onset of symptoms (FM3).  FM pools were hybridized 
against one pool of controls from the con_SAL set (50 samples). 
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The resulting data was analyzed with Agilent’s Genomic Workbench software, using the 
ADM-2 algorithm. We selected regions with at least three aberrant probes and a smoothed 
log2ratio >0.3 (2 standard deviations). 
Validation of array results 
Breakpoints were detected by PCR amplification of the deleted allele based on data from 
Conrad et al. [6], followed by sequencing of the amplified products and BLAT alignment. 
Multiplex reactions for each CNV, including primers for both the deleted and non-deleted 
forms, were designed for genotyping. PCR conditions for the different experiments are 
described in supplementary methods. 
CNV genotyping reactions included both samples from FM cases and controls in order to 
avoid possible bias, non-template controls and, when available, positive controls (HapMap 
samples with validated genotypes for each CNV [6]). NRXN3_del was also assessed by a 
Veracode assay as described [10].  
Allelic association analysis was performed with Fisher exact test. Genotypic association 
analyses were performed using binomial and multinomial regression models for case-
control and among fibromyalgia clusters studies respectively. Quality control and 
association analyses of the Veracode assay were performed with PLINK software. 
 
RESULTS 
Genome-wide association study 
SNP genotyping analysis highlights the involvement of genes in neurological pathways 
After QC procedures, 505,454 SNPs were considered for allelic association analyses in 300 
FM and 203 controls. These samples did not show evidence of population stratification, as 
illustrated by the QQ plot (Figure 1) and the genomic inflation value (λ = 1.013). Association 
analysis did not yield any SNP association over the GWAS significance threshold, as shown 
in the Manhattan plot (Figure 2). Nevertheless, some possible association peaks emerged at 
chromosomes 3 and X, and eight SNPs showed p-values <1x10-5, while another 69 had p-
values <1x10-4. 
These top 77 SNPs (p-value <1x10-4) (Supplementary Table 4) were selected to perform 
pathway analysis. Out of the 77 gene IDs introduced in IPA, 53 were mapped. IPA pathway 
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analysis identified two top networks that were overrepresented in our geneset: 
reproductive system disease (16 genes) and neurological disease (12 genes). Thirty-one of 
the 77 gene IDs were mapped in Geneset analysis Toolkit to perform GO analysis, 
identifying two main molecular functions: protein binding and ion binding, with 16 and 14 
genes, respectively; in these categories, the analysis also identified metal ion binding as the 
only statistically significant overrepresented molecular function (p-adjusted <0.05, 
Benjamini correction). 
Replication 
Twenty-one of the top 77 SNPs were selected for replication in a larger cohort, after a 
prioritization step based on imputation data and gene function. Replication was performed 
only in females. After QC procedures, 20 SNPs in 940 cases and 601 controls were 
considered for the replication analysis. We performed allelic association tests. In the 
replication data we observed significant evidence of SNP-effect sizes in the same direction 
as the discovery set (9/17). Only one of these SNPs, rs11127292, located in the MYT1L 
(myelin transcription factor 1-like) gene, showed association (p <0.05) (Table 1). Based on 
17 (21, 1 no HWE, 3 not independent) independent SNPs taken forward, we would expect 
0.05x17 = 0.85 to reach p = 0.05 by chance. 
 We then applied the subphenotyping of the samples [9], and three subphenotype cohorts 
were tested for association for the four SNPs showing the strongest joint p-values. Again, 
rs11127292 showed association in female FM cases with low levels of comorbidities and 
high levels of symptomatology (joint p-value = 4.28 x 10-5) (Table 2). Potential functionality 
of this SNP was tested by Genvar cis-eQTL-SNP analysis, which showed a correlation trend 
(p=0.0091, while the empirical threshold for significance is 0.0086) between this SNP and 
expression levels of STNG2 (one expression probe) (supplementary figure 3). Assessing 
functional significance of this SNP with Puppasuite or Regulomedb did not highlight any 
other potential functionality. 
CNV analysis identifies NRXN3 as a novel FM gene 
We detected seven regions showing differential hybridization between FM and control 
pools both in direct and dye swap hybridizations (Supplementary table 5). Three of these 
regions (WDR60, DOCK5 and SIRPB1), were not considered for replication since they 
repeatedly appeared in the aCGH experiments performed in the laboratory for different 
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disorders (data not shown). An additional region detected by the less restrictive ADM-1 was 
also considered for validation as a functional candidate. 
We attempted to validate the remaining four regions coming from ADM-2 analysis, and the 
ADM-1 detected region, MYO5B. We mapped or confirmed CNV breakpoints (GALNTL6: 
rs67651552; PTPRD: rs71315285; MYO5B: rs72192652; WWOX: hg18_chr16: 76929139-
76942400; and NRXN3:hg18_chr14:79175982-79184862) and designed multiplex PCR 
experiments for genotyping. Genotyping was performed first in a subset of 345 FM samples 
(selected randomly from FM_discovery and FM_replication) and 133 controls from con_SAL, 
and, if aCGH findings were supported, in our entire cohort (FM_discovery + FM_replication 
and con_SAL). Only one CNV (NRXN3) was considered for genotyping in the entire cohort. 
The CNV located in the intronic region of NRXN3 showed support for association in the 
initial genotyping step. Genotyping of the initial subset of 345 FM cases and 133 controls 
confirmed the results observed in the pools, showing an association of the deleted allele 
with FM (genotypic association, recessive model p = 9.215x10-5, OR (95%CI) = 3.29 (1.69-
6.41); allelic association p = 0.16 Fisher Test). We then completed the genotyping of our 
entire cohort (genotypic association, recessive model p = 0.021, OR (95%CI) = 1.46 (1.05-
2.04); allelic association Fisher Test p = 0.015, OR (95%CI) = 1.22 (1.03-1.43)), which 
validated the association. 
We then applied the cluster classification described previously [9] and performed 
association analyses for each of the FM clusters against the controls. The significance of the 
association of the deleted allele with FM was maintained when selecting samples with low 
levels of comorbidities (clusters 1 and 3) (genotypic association, recessive model p = 0.019, 
OR (95%CI) = 1.49 (1.06-2.11); allelic association Fisher Test p = 0.004, OR (95%CI) = 1.27 
(1.07-1.50)). The genotypic distribution in the different subsets is summarized in Tables 3 
and 4.  
 
DISCUSSION  
We have explored the genetic susceptibility to FM through GWAS and aCGH assessment of 
CNVs. Our findings identify two associated variants, a SNP in MYT1L, and an intronic CNV in 
NRXN3. Both results suggest a possible role for the central nervous system in FM genetic 
susceptibility. 
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None of the SNPs reached genome-wide significance, but we observed signal peaks at 
chromosomes 3 and X, and identified 77 SNPs with p-values <1x10-4. Since recent studies 
detected linkage to chr17 [1], and association in chr5 [30], we specifically checked our 
GWAS signals in these regions. Among the top 77 SNPs, four were located in chr17 and one 
in chr5, although outside the reported linkage or association regions. Twenty-one SNPs, 
including one in chr17, were selected for replication in a large independent FM cohort. Nine 
of the SNPs showed an effect in the same direction than those identified in the discovery 
cohort, and one, rs11127292, had a nominally significant p-value. 
rs11127292 is located in the third intron of MYT1L, and may be correlated to expression 
levels of SNTG2 in lymphocytes. Both MYT1L and SNTG2 are good candidates for FM: they 
are involved in neuronal pathways, and FM could be characterized by a central nervous 
system (CNS) dysfunction [36]. MYT1L is involved in neuronal differentiation [31; 40], and 
variants in this gene have been associated with neuropsychiatric disorders [25; 41; 42], 
while variants in SNTG2 have been associated to autism [46] and to suicide attempts in 
major depression [29]. 
The potential role for the CNS dysfunction in FM was not only highlighted by the association 
of rs11127292. Neurological disease was one of the two top networks identified by IPA 
analysis of the 77 GWAS top SNPs. Furthermore, Geneset GO analysis showed ion binding 
(and calcium in particular) as one of the two main molecular functions, calcium channel 
complex as the top molecular component, and regulation of calcium mediated signalling 
and calcium ion transport and neurogenesis among the top ten biological functions. These 
results suggest an involvement of the CNS in fibromyalgia, supporting the hypothesis that 
FM could be due to a dysfunction in pain processing. 
Nevertheless, we have to take these results with care since this GWAS presents as its main 
limitation the reduced number of samples considered. Although the samples were carefully 
selected to attain a more homogeneous phenotype, the high genetic and phenotypic 
heterogeneity of FM, coupled with the small discovery sample size, could explain why we 
were not able to detect an association reaching GWAS significance. The small sample size 
could also result in the detection of false positives and a consequent lack of replication of 
associated variants. Since we used a different genotyping platform for the controls, despite 
performing careful QC, some technical bias could remain leading to false positives. 
Nevertheless, the association of rs11127292 was confirmed in the replication phase, and 
stratified analysis improved the replication results, highlighting the importance of a precise 
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10 
phenotyping of the samples in dissecting the genetic components of extremely complex 
disorders like FM.  
We also explored the contribution of CNVs to FM genetic susceptibility using aCGH with a 
pooling strategy. Seven regions showed differential hybridization in aCGH experiments, one 
of which, an intronic 8kb deletion within the NRXN3 gene, was validated on follow-up. 
Further subsetting of the samples also increased the significance of the association in those 
samples with low levels of comorbidities. We could not confirm an association for the CNVs 
within GALNTL6, WWOX, PTPRD and MYO5B, but their participation in FM cannot be 
completely excluded, as they could be low effect variants, requiring larger cohorts for 
validation. These genes have been shown to play a role in the CNS [22; 23; 34; 38], and 
considering our GWAS and aCGH results, this would make them good candidates for FM 
susceptibility. 
The use of pooled samples presents clear economic advantages, but it can also lead to a 
higher number of false positives. Causes of false positives can be due to real but random 
differences in the frequencies between cases and controls, or to unequal sample 
contributions to the pools, leading to biased overrepresentation of rare variants. In order to 
overcome these limitations, we used three independent pools of FM as biological 
replicates. All three FM pools were hybridized against the same control pool, which had 
been frequently tested in the laboratory. Variants recurrently appearing in other 
hybridizations with this control pool were filtered out. In addition, direct and ‘dye-swap’ 
experiments were performed. Nevertheless, only one of the five regions selected for 
follow-up showed association with FM in the larger cohort. 
An intronic CNV in NRXN3 was associated with FM with low levels of comorbidities. NRXN3 
is a good candidate for FM as it is essential for neuronal development and for signal 
transmission. Neurexins are among the most widely studied adhesion and scaffolding 
molecules involved in synapse stability and function. They are transmembrane proteins 
located in the presynaptic neuron. They have three extracellular binding partners: 
neuroligins, dystroglycan and neurexophilins [7]. In particular, the binding with neuroligins 
is essential for the development and function of GABAergic and glutamatergic synapses 
[37]. Several variants in neurexin genes (rare CNVs and SNPs) have been associated with 
different phenotypes, mainly neuropsychiatric disorders, including addictive behavior [16; 
20] and obesity [15]. Changes in NRXN3 and therefore in signal transmission could explain 
the central nervous pain dysfunction characteristic of FM. 
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The detected NRXN3 variant is an intronic CNV. We tried to identify a possible link to other 
functional variants by genotyping additional NRXN3 variants in the FM samples, 
unsuccesfully (data not shown). We then considered possible functional consequences of 
the CNV at the mRNA level. NRXN3 has several different isoforms generated by alternative 
splicing. One of the alternative splicing sites is located relatively close to the CNV. 
Preliminary data from two neuronal cell lines indicate that the CNV could affect differential 
skipping of exon 20, which encodes a protein domain involved in binding to neuroligins 
[44], although data from lymphoblastoid cell lines do not support this hypothesis. In order 
to extract a definite conclusion regarding the correlation between exon-skipping and the 
CNV, it would be advisable to test additional neuronal cells with different genotypes for the 
deletion, as it is possible that the splicing behavior changes between lymphoblastoid and 
neuronal lineages.  
Although our results correspond to the analysis of a small initial dataset, we have found 
further support in a larger, well-characterized cohort, especially when selecting for a 
specific phenotype. It would be particularly interesting to follow up on our results by 
validation of the specific findings in additional large, well characterized, cohorts. This is 
challenging in FM since, to our knowledge, this cohort is the largest existing FM DNA 
collection. 
The two identified FM associations, the SNP in MYTL1 and the CNV in NRXN3, were slightly 
improved after subphenotyping. This indicates that identifying homogeneous phenotypes 
constitutes a key step for the identification of FM genetic susceptibility factors. The slight 
improvement in the association scores further validates the cluster-based classification 
used, indicating that cases with low levels of comorbidities form a more genetically 
homogeneous subset of FM cases. 
In summary, our GWAS and aCGH results point at a role for the CNS in FM genetic 
susceptibility. In fact, variants detected by both studies are linked: calcium transport 
appears as one of the main GWAS molecular functions, and the neurexins-neuroligins 
complex formation is dependent on calcium [26]; also, the SNP showing the strongest 
association has been correlated with expression levels of SNTG2 (in blood) and SNTG2 
interacts with neuroligins 3 and 4, which are neurexin partners [46]. Furthermore, another 
study evaluating gene expression of FM individuals detected changes in genes implicated in 
pain transmission, which would support our findings [24]. This CNS implication in FM would 
be further supported by recently published findings on pain, showing evidence for specific 
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neurophysiologic alterations in FM patients [39]. Of particular interest, functional and 
morphological impairment of small fibers have been reported in FM cases. Individuals 
presenting those electrophysiological changes would be the ideal models to explore the 
association and functionality of our detected genetic variants in order to try to establish a 
correlation with clinical severity, outcome and response to treatment. 
In spite of the difficulties encountered in the study of genetic factors of FM (clinical 
heterogeneity, reduced availability of replication cohorts and non-availability of target 
tissue) we have been able to detect variants that can shed a light on genetic factors 
determining FM susceptibility. To our knowledge, only neurotransmitter related genes 
(including receptors, transporters and enzymes implicated in neurotransmitters 
metabolism) had been tested as FM susceptibility candidates. The possible role of synaptic 
structural molecules such as NRXN3 and molecules implicated in CNS development and 
functioning, such as MYTL1, open a new wide field of research on aetiology and drug 
targets. One consideration that we have to take into account is that all of these molecules 
have been previously associated with neuropsychiatric disorders. If these synapse genes 
associations are confirmed in other FM cohorts, it would constitute an additional argument 
to consider FM as a neuropsychiatric disorder. 
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FIGURE LEGENDS: 
Fig. 1: QQ plot of fibromyalgia GWAS. Observed p-values are plotted against expected p-
values in an association study of 500 k SNPs. The almost perfect correlation between 
observed and expected values was indicative of absence of population stratification as 
proven by a genomic inflation (λ) value of 1.013. Figure obtained with WGA viewer 
software. 
Fig. 2: Manhattan plot representing the results of the fibromyalgia GWAS. The negative 
LOG10 p-values of all SNPs are plotted against their chromosomal positions. Chromosomes 
are represented by different colors. 
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SUMMARY 
Variants in NRXN3 and MYT1L are associated with fibromyalgia. Our results point to a role for 
the central nervous system in susceptibility to fibromyalgia. 
*Summary
Figure 1
Click here to download high resolution image
Figure 2
Click here to download high resolution image
Table 2. rs11127292 allelic association in the different fibromyalgia clusters in GWAS, replication and joint cohorts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F: frequency of the effect allele (minor allele; A or T in rs1112792); Discovery: FM_discovery vs CON_discovery; Replication: 
FM_replication vs CON_VH + CON_SAL; FM: fibromyalgia individuals; C: controls; cl1, cl2, cl3, cl1_3: clusters 1, 2, 3, and 1 
and 3, respectively. 
rs11127292 F_FM F_CONTROLS P-value OR (95%CI) 
Discovery  (300 FM vs. 203 C) 0.051 0.125 2.6x10-5 0.37 (0.23-0.60) 
Replication (940 FM vs. 592 C) 0.091 0.114 0.03 0.76 (0.60-0.97) 
Discovery + Replication (1240 FM vs. 795 C) 0.081 0.117 1.76x10-4 0.67 (0.54-0.82) 
Discovery cl3 (196 FM vs. 203 C) 0.045 0.125 6.21x10-5 0.33 (0.19-0.58) 
Replication cl3 (450 FM vs. 592 C) 0.083 0.114 0.019 0.70 (0.52-0.94) 
Discovery cl1 + Replication cl1 (240 FM vs. 795 C) 0.085 0.117 0.05 0.70 (0.49-1.01) 
Discovery cl2 + Replication cl2 (304FM vs. 795 C) 0.092 0.117 0.09 0.76 (0.55-1.04) 
Discovery cl3 + Replication cl3 (646 FM vs. 795 C) 0.071 0.117 4.28x10-5 0.58 (0.44-0.75) 
Discovery cl1_3 + Replication cl1_3 (886 FM vs. 795 C) 0.075 0.117 4.03x10-5 0.61 (0.48-0.77) 
Table
Table 3. Genotype distribution of NRXN3_DEL among cases and controls in the studied cohorts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Del: Deleted; NoDel: Non-deleted; CON: Control; FM: Fibromialgia (FM_discovery + FM_replication); FM cl1, FM cl2, FM cl3, FM 
cl1_3: Fibromyalgia cases corresponding to clusters 1, 2, 3, and 1 and 3, respectively. 48 FM samples could not be assigned to 
a cluster. 
GENOTYPES 
CON = 445 
N (%) 
FM = 1358 
N (%) 
FM cl1 = 268 
N (%) 
FM cl2 = 330 
N (%) 
FM cl3 = 712 
N (%) 
FM cl1_3 = 980 
N (%) 
Del/Del 48 (10.8) 204 (15.0) 50 (17.5) 497(14.2) 103 (14.5) 150 (15.3) 
Del/NoDel 207 (46.5) 640 (47.1) 132 (47.4) 146 (44.2) 349 (49.0) 476 (48.6) 
NoDel/NoDel 190 (42.7) 514 (37.8) 95 (35.1) 137 (41.5) 260 (36.5) 354 (36.1) 
Table
Table 1. SNPs selected for replication in our GWAS study of fibromyalgia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNPs are listed in ascending order according to allelic association GWAS p-value (with the exception of the three imputed SNPs). Type indicates the relative 
position of the SNP with respect to the nearest gene, and gene provides the gene in which the SNP is located or the nearest gene in a 500 kb window. IM: 
imputed SNP. Type: SNP location upon the gene according to WGA viewer classification; ‡ rs2901761 was not in HWE in controls (p-value = 0.005). 
 
SNP Rank Type Gene/Region P GWAS OR (95%CI) P replication OR (95%CI) Combined P  OR (95%CI) 
rs12556003 1 intron MCF2 2.14x10-6 0.34 (0.21-0.54) 0.132 0.81 (0.62-1.06) 1.98x10-4 0.65 (0.52-0.81) 
rs12704506 2 intergenic STEAP1/STEAP2 3.20x10-6 2.19 (1.56-3.07) 0.010 0.81 (0.67-0.96) 0.9 1.00 (0.86-1.17) 
rs11923054 3 intron ZBBX 3.52x10-6 0.54 (0.42-0.70) 0.580 0.93 (0.80-1.08) 0.0047 0.83 (0.73-0.94) 
rs2858166 4 5 kb_down ARMCX6 3.61x10-6 1.83 (1.42-2.38) 0.695 0.99 (0.86-1.15) 0.008 1.18 (1.04-1.34) 
rs10782344 5 intergenic RP11-518I13.1 3.63x10-6 2.22 (1.57-3.12) 0.526 1.07 (0.89-1.28) 0.004 1.26 (1.07-1.48) 
rs1998709 6 intron PLCE1 7.62x10-6 1.80 (1.39-2.33) 0.14 0.87 (0.75-1.02) 0.3397 1.06 (0.93-1.21) 
rs2901761 IM Intron PLCE1 5.11x10-7 0.50 (0.38-0.66) ‡ ‡ ‡ ‡ 
rs2194390 7 intron NRXN1 8.06x10-6 0.41 (0.21-0.67) 0.702 1.07 (0.84-1.35) 0.049 0.81 (0.67-0.99) 
rs2701106 8 intergenic TBX5 8.94x10-6 1.84 (1.40-2.42) 0.287 0.90 (0.77-1.05) 0.194 1.09 (0.95-1.24) 
rs7963168 IM intergenic TBX5 1.49x10-8 0.52(0.40-0.67) 0.08 1.17 (1.01-1.36) 0.28 1.07 (0.94-1.22) 
rs17512210 15 intron SHISA6 2.21x10-5 0.56(0.43-0.73) 0.851 1.01 (0.86-1.17) 0.049 0.87 (0.76-0.99) 
rs9381682 18 intergenic - 2.48x10-5 0.45 (0.31-0.65) 0.156 0.87 (0.69-1.09) 7.38x10-4 0.72 (0.59-0.87) 
rs11127292 20 intron MYT1L 2.60x10-5 0.37 (0.23-0.60) 0.039 0.76 (0.60-0.97) 1.76x10-4 0.67 (0.54-0.82) 
rs12770855 32 intergenic ZNF438 4.05x10-5 0.41 (0.27-0.63) 0.149 0.85 (0.67-1.07) 0.001 0.71 (0.58-0.87) 
rs10821659 33 intron ANK3 4.06x10-5 0.58 (0.44-0.75) 0.110 0.88 (0.73-1.03) 6.22x10-4 0.79 (0.70-0.90) 
rs265015 34 intron UNC5C 4.12x10-5 0.41 (0.26-0.63) 0.016 1.41 (1.06-1.88) 0.852 0.97 (0.77-1.23) 
rs9565180 37 intron LMO7 4.53x10-5 0.54 (0.41-0.73) 0.242 1.13 (0.94-1.35) 0.267 0.91 (0.79-1.06) 
rs6043433 43 intron MACROD2 5.00x10-5 0.52 (0.38-0.71) 0.288 1.11 (0.91-1.36) 0.899 0.89 (0.76-1.06) 
rs6131711 IM intron MACROD2 9.92x10-8 1.87 (1.45-2.83) 0.596 1.05 (0.91-1.23) 9x10-4 1.25 (1.09-1.42) 
rs11602757 57 intron LRG_164 7.15x10-5 2.77 (1.64-4.68) 0.795 0.95 (0.74-1.23) 0.077 1.22 (0.97-1.53) 
rs981524 67 intron AKAP6 7.94x10-5 1.98 (1.40-2.81) 0.139 1.18 (0.99-1.42) 0.001 1.30 (1.11-15.52) 
Table
Table 4. Allele distribution of NRXN3_DEL among cases and controls in the 
studied cohorts. 
 
 
 
 
 
 
 
Del: deleted; NoDel: non-deleted; CON: con_VH + con_SAL; FM: FM_discovery + 
FM_replication; Cl1: cluster 1; Cl3: cluster 3. 
ALLELES CON (%) FM (%) FM (cl1+cl3) (%) 
NoDel 587 (65.9) 1668(61.4) 1184 (60.4) 
Del 303 (34.1) 1048(38.6) 776 (39.6) 
Table
SUPPLEMENTARY MATERIAL 
SUPPLEMENTARY METHODS 
Genome-wide association study 
Quality control 
Quality control (QC) was performed with PLINK software. In order to minimize platform bias, 
QC steps were executed separately in the FM and control datasets, taking only into account 
the SNPs that overlapped between the two datasets (582,892 SNPs). Samples were checked 
for origin, heterozygosity, genotyping rate, inbreeding and gender. Sample filtered datasets 
were then filtered at the SNP level considering genotyping rate (≥96%), Hardy Weinberg 
Equilibrium (p>0.0001) and minimum allele frequency (MAF) ≥5%. After QC at the sample and 
SNP levels, the FM dataset included 308 cases (300 females and 8 males) and 513,897 SNPs, 
and the control dataset 395 controls (203 females and 192 males) and 512,615 SNPs. Then, FM 
and control datasets were merged with 505,454 overlapping SNPs. Since 97% of the FM 
samples were females we only included female controls to have a gender matched control set. 
Imputation 
For GWAS regions showing positive signals, we performed imputation in a window span of 
100kb with Impute v2 (http://mathgen.stats.ox.ac.uk/impute/impute_v2.html) 
(Supplementary methods), considering an interval buffer region of 500 kb and using as 
reference panels 1000Genomes and Hapmap3 CEU data. Association analysis of imputed data 
was performed with SNPTEST (http://mathgen.stats.ox.ac.uk/genetics), which allows dealing 
with genotype uncertainty due to the imputation process. For this we used the score approach 
based on missing data likelihood score test. Only SNPs with an Infoscore >0.8 were taken into 
consideration. 
Cluster analysis 
A full description of the cluster analysis is provided in ref. 9. Briefly, the full 1500 fibromyalgia 
samples cohort was randomly divided in two sets. The cluster analysis of the clinical variables 
was performed in one of the sample sets and validated in the second set. Then, two sets of 
variables were used to score all samples, which were a priori divided into three clusters by K-
means analysis. A post-hoc labeling of the clusters based on their clinical characteristics was 
applied.  A few individuals could not be classified into clusters as some of the necessary 
variables were not available. The cluster distribution of the samplesfrom each cohort is given 
below: 
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  Cluster1 Cluster2 Cluster3 
FM_discovery (291) 66(22.7%)    29(10%) 196 (67.3%) 
FM_Replication(1135) 217(19.1%) 328(28.9%) 590 (52%) 
Joint (1398) 283(20.2%) 357(25.6%) 758 (54.2) 
 
CNV analysis: WWOX Breakpoints detection 
PCR conditions 
Primers (Table S1) were designed with Primer3 software taking into account aCGH positive 
probes coordinates and overlapping CNVs described in the Database of Genomic Variants. We 
took advantage of data available in Conrad et al work and included, as positive controls, 
HapMap samples with known genotypes for the CNV (Two copies: NA07019, NA06994; One 
copy: NA12056, NA12145, NA12864; Zero copies: NA06991; NA12761).  
Table S1. Primers used for WWOX breakpoints detection. 
CNV Primers (5’-3’) Product size (bp) 
WWOX WWOX_F1: TGGGTAGGAATCCTGCAGAC 
WWOX_R1: TGCCTAAAAGCACACACTGC 
WWOX_R2: GGGCATCCCAGTTTTCTACC 
WWOX_R3: CCTGCTTCCTGAACATTCCT 
Depending on primers 
combinations 
 
PCR reaction was performed following the PCR program below: 
2’ 94ºC and 30 cycles: 30” 94ºC; 30” 60ºC; 45” 68ºC; 7’ 68ºC 
Mix components: 
50 ng DNA; 10x Roche® PCR reaction buffer + Mg+2; 0.2 mM dNTPs; 0.4 pM/l each primer 
0.1 U/l Taq Polymerase; H2O to reach a final volume of 25 l. 
Removal of PCR primers and reagents 
5 l PCR product of homozygous deleted samples were cleaned up with 2 l of USB® Exo-SAP-
IT® following an incubation of 15’ at 37ºC plus 15’ at 80ºC. 
Sequencing PCR 
1 l of PCR product after Exosap, was added to a mix of 1 l Big Dye Terminator® v3.1 (Applied 
Biosystems), 1.5 l 5X Buffer, 0.5 l of either reverse or forward primer (10 µM) and 6 l H2O, 
and a sequencing PCR reaction was performed following the PCR program below (30 cycles): 
30” 95ºC; 30” 50ºC; 3’ 60ºC 
Purification sequencing PCR 
Sequencing PCR products were purified with sepharose (Sephadex®-G50) columns. Briefly, 800 
µl of sepharose were pipetted into a column and centrifuged at 1000 g for one minute for 
sepharose compactation. Flow-through was discarded and 10 µl of water were added to the 
sepharose column and centrifuged for one minute again at 1000g. Finally, the column was 
introduced in a new eppendorf, the sequencing PCR loaded into the column and centrifuged 
for 1 min at 1000g. The purified PCR was run in a capillary sequenced (3730XL Applied 
Biosystems). 
Sequence analysis and blast to human genome 
Sequencing results were analyzed with CLC workbench with standard settings. Only clean 
sequences were selected for blast analysis in UCSC Genome Browser.  
CNVs genotyping 
PCR conditions 
PCR conditions and primers for CNVs genotyping are summarized in Tables S2 and S3 below. 
Table S2. PCR conditions for CNV genotyping. Grey cells correspond to shared components in 
between reactions 
 ACACA GALNTL6 WWOX MYO5B PTPRD NRXN3 
PCR program 
(30 cycles) 
2’ 94ºC 
30” 94ºC 
30” 60ºC 
1’ 72ºC 
7’ 72ºC 
2’ 94ºC 
30” 94ºC 
30” 63ºC 
30” 72ºC 
25’ 72ºC 
2’ 94ºC 
30” 94ºC 
30” 61ºC 
30” 72ºC 
7’ 72ºC 
2’ 94ºC 
30” 94ºC 
30” 62ºC 
30” 72ºC 
7’ 72ºC 
2’ 94ºC 
30” 94ºC 
30” 60ºC 
30” 72ºC 
7’ 72ºC 
2’ 94ºC 
30” 94ºC 
30” 60ºC 
30” 72ºC 
7’ 72ºC 
Mix components       
50 ng DNA - 75 ng - - - - 
10x Roche® PCR reaction 
buffer+Mg
+2
 
- - - - - - 
dNTPs (mM)  0.125 0.06 0.125 0.2 0.2 0.15 
Del Primers (pM) 0.40 0.02 0.4 0.4 0.24 0.4 
Non-Del primers (pM) 0.24 0.032 0.4 0.4 0.24 0.2 
Taq Polymerase (U)  0.1 0.06 0.1 0.06 0.06 0.02 
H2O to volume of 25 l - - - - - 15l 
 
 
Table S3. Primers for CNV genotyping PCR reactions 
Allele 
Primers (5’-3’) Product size (bp) 
ACAC Del 
 
ACACA Non-Del 
ACACA_DelF: GGCCTCCTCTTCTAGCTGTTG 
ACACA_DelR: AACAGGTGCCCAATAAATGC 
ACACA_F: GAGCCCATTAATCCAGAAAGG 
ACACA_R: TGACTTAGTGCCCATTCAAGG 
1164 
 
449 
GALNTL6 Del 
 
GALNTL6 Non-Del 
FF_Mi_A: [6FAM]GCAAGTAATGCCCAAGGAAA 
RF_Mi_del2: AGAGCATAAACCTCACAGGAC 
FF_Mi_wt: [6FAM]TGGTAATGAGCAGAGGAAAGG 
RF_Mi_wt5: TGAGCACTTACCCTGTCTGC 
250 
 
283 
WWOX Del 
 
WWOX Non-Del 
WWOX_DelF: ATCTGGCCATGTCCTCATTT 
WWOX_DelR: TGTGACCTGATAACCGCTGA 
WWOX_F: AATGGGAATCTTTGCCTGTG 
WWOX_R: ATGGCAACTGACTTGGGAAG 
192 
 
217 
MYO5B Del 
 
MYO5B Non-Del 
MYO5B_DelF: AACAGGCTGTCTCTTCCATGA 
MYO5B_DelR: CAGGGGTGGTTAGAATGAGG 
MYO5B_F: GAATGCATTTTGTCCAGCAGT 
MYO5B_R: CTCATAGAGGCGGTGTTCTTG 
234 
 
201 
PTPRD Del 
 
PTPRD Non-Del 
PTPRD_DelF: GGGTGGTGGAAGGTGGTTAT 
PTPRD_DelR: GGTCTGGCATTTTGACATGA 
PTPRD _F: GCCAATTTCAGATCCTCAGC 
PTPRD _R: TTAGTGGCGTTCACACATGG 
450 Del 
980 Non-Del 
219 
NRXN3 Del 
 
NRXN3 Non-Del 
NRXN3_FDel: CAGTCTTGACTGCTGGGTGAAC 
NRXN3_R: [6FAM]GTGACTGCTGATGAGCCACGC 
NRXN3_FNodel: GTGAGCACTCGATCCAGCATAA 
NRXN3_R: [6FAM]GTGACTGCTGATGAGCCACGC 
466 
 
350 
 
PCR products detection 
PTPRD PCR products were loaded in a 2% agarose gel and visualized with a UV transilluminator 
(Gel Doc® (Bio Rad)). WWOX and MYO5B PCR products were loaded in a 3% agarose gel and 
visualized with a UV transilluminator (Gel Doc® (Bio Rad)). 
GALNTL6 CNV and NRXN3_DEL were genotyped by multiplex PCR with 5’ FAM modification, 
followed by capillary electrophoresis in a 3730XL automatic sequencer and analysis with the 
Gene Mapper package (Applied Biosystems, Foster City, CA). Analysis was performed with the 
Gene Mapper package (Applied Biosystems). Samples showing peak intensities below 1000 
fluorescent units or ratios of deleted allele to non-deleted allele <0.2 or >5 were not 
considered for analysis. For capillary detection, NRXN3_DEL PCR reactions were diluted at 
1:15, and 1 µl of PCR dilution was then added to 9 µl of a formamide/ROX mixture (950 µl + 20 
µl per 100 samples), and samples were loaded into 3730XL. GALNTL6 PCR products were not 
diluted: 1 µl of the PCR was added to the formamide/ROX mixture.  
NRXN3_del was also assessed with 3 SNPs included in a Veracode assay. Two of the SNPs were 
located within the deleted region (rs12894142 and rs12100748), and we designed a third SNP 
assay (NRXN3del) with each of its extension probes flanking the breakpoints of the CNV. A 
combination of the results for these SNPs was used to assess the genotype. A sample was 
considered as homozygous deleted when failing in both SNPs included in the deleted region 
and amplyfing in the breakpoints SNP; an heterozygous sample for the CNV was defined by 
presenting genotype for the three SNPs (the two inside the deletion having to be mandatorily 
homozygous); the homozygous non deleted samples were characterized by the failure of the 
breakpoints SNP and presenting genotype at the SNPs inside the CNV region (being either 
homozygous or heterozygous). 
  
SUPPLEMENTARY RESULTS 
Table S4. SNPs showing the strongest allelic associations (p-value <10-4) 
SNP P-value Chromosome Coordinate (Hg18) Gene/Region 
rs12556003 2,14x10-6 X 138743267 MCF2 
rs12704506 3,20x10-6 7 89621311 STEAP1/STEAP2 
rs11923054 3,52x10-6 3 167051769 ZBBX 
rs2858166 3,61x10-6 X 100875273 ARMCX6 
rs10782344 3,63x10-6 6 156778660 RP11-518I13.1 
rs1998709 7,62x10-6 10 95884574 PLCE1 
rs2194390 8,06x10-6 2 50902931 NRXN1 
rs2701106 8,94x10-6 12 114697547 TBX5 
rs9525923 1,11x10-5 13 44783715 RP11-478K15.2 
rs1347532 1,12x10-5 16 60615455 RP11-51O6.1 
rs12486010 1,53x10-5 3 166942627 ZBBX 
rs7616572 1,61x10-5 3 167046536 ZBBX 
rs10894241 1,75x10-5 11 130635852 AP003486.1 
rs11925091 2,00x10-5 3 166944651 ZBBX 
rs17512210 2,21x10-5 17 11230466 SHISA6 
rs5951332 2,35x10-5 X 100743826 ARMCX4 
rs7060491 2,35x10-5 X 100754149 ARMCX4 
rs9381682 2,48x10-5 6 48620238 AL391538.1 
rs17689185 2,50x10-5 16 77525081 AC025284.1 
rs11127292 2,60x10-5 2 2029943 MYT1L 
rs6523526 2,64x10-5 X 100917910 ARMCX2 
rs3784820 2,76x10-5 16 1569252 IFT140 
rs6621083 2,81x10-5 X 100760626 OTTHUMG00000022030 
rs10432656 2,82x10-5 2 33375032 OTTHUMG00000152118 
rs2071222 3,00x10-5 X 100617372 LRG_128 
rs11971008 3,05x10-5 7 82136025 CACNA2D1 
rs858939 3,10x10-5 2 50971951 NRXN1 
rs11187789 3,23x10-5 10 95871655 RP11-162K11.4 
rs13068321 3,46x10-5 3 167013777 ZBBX 
rs963618 3,79x10-5 X 100743037 ARMCX4 
rs9296606 3,91x10-5 6 48640714 AL391538.1 
rs12770855 4,05x10-5 10 31120198 ZNF438 
rs10821659 4,06x10-5 10 61793424 ANK3 
rs265015 4,12x10-5 4 96360796 UNC5C 
rs882847 4,39x10-5 17 4382729 SPNS3 
rs10507243 4,43x10-5 12 114708798 TBX5 
rs9565180 4,53x10-5 13 76231470 OTTHUMG00000017093 
rs4680657 4,61x10-5 3 166894537 AC112501.2 
rs1994979 4,68x10-5 17 4350990 SPNS3 
rs259154 4,72x10-5 7 89626822 OTTHUMG00000065036 
rs13238853 4,73x10-5 7 135959346 OTTHUMG00000155618 
rs4148965 4,75x10-5 18 9109484 NDUFV2 
rs6043433 5,00x10-5 20 15659486 MACROD2 
rs6537129 5,49x10-5 4 143779613 INPP4B 
rs9299090 5,68x10-5 9 9264932 AL353733.1 
rs5951269 5,99x10-5 X 100778274 ARMCX4 
rs11869601 6,19x10-5 17 11234035 SHISA6 
rs9410632 6,27x10-5 9 90400909 CTSL3 
rs259152 6,42x10-5 7 89626611 OTTHUMG00000065036 
rs8034595 6,43x10-5 15 96719229 AC016251.2 
rs4986649 6,43x10-5 X 100736761 ARMCX4 
rs265018 6,52x10-5 4 96362497 UNC5C 
rs7022749 6,61x10-5 9 90405495 CTSL3 
rs309853 6,62x10-5 8 29873603 OTTHUMG00000163815 
rs10507833 6,97x10-5 13 76226139 OTTHUMG00000017093 
rs4910595 7,15x10-5 11 4049129 STIM1 
rs11602757 7,15x10-5 11 4053881 STIM1 
rs2920137 7,15x10-5 11 4079318 STIM1 
rs6719219 7,19x10-5 2 2010779 MYT1L 
rs1938204 7,24x10-5 6 48787015 AL391538.1 
rs6083017 7,28x10-5 20 23119766 RP4-737E23.4 
rs12588013 7,29x10-5 14 62724837 AL390816.1 
rs9643612 7,39x10-5 8 50430756 RP11-738G5.1 
rs2065703 7,53x10-5 20 31966698 CDK5RAP1 
rs7314743 7,55x10-5 12 114718647 TBX5 
rs2009626 7,84x10-5 3 187600404 RP11-44H4.1 
rs981524 7,94x10-5 14 33186257 AKAP6 
rs6778044 8,16x10-5 3 187594092 RP11-44H4.1 
rs5951340 8,24x10-5 X 100771055 ARMCX4 
rs1323851 8,36x10-5 1 64450437 ROR1 
rs12744386 8,80x10-5 1 24168019 HMGCL 
rs6966421 9,18x10-5 7 155329530 CNPY1 
rs6556373 9,25x10-5 5 158359476 EBF1 
rs2997370 9,42x10-5 6 48778106 AL391538.1 
rs10184672 9,42x10-5 2 11198448 AC062028.1 
rs2009627 9,68x10-5 3 187600359 RP11-44H4.1 
rs5991939 9,73x10-5 X 100712422 ARMCX4 
SNPs are listed on descending order based on p-value. SNPs selected for replication appear in bold. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TableS5: Analysis of copy number variants (CNV) in pooled samples of fibromyalgia 
 
 
 
 
 
 
 
 
 
 
 
Results are based on hybridization with the 400k-CNV aCGH; genomic locations are based on build Hg 18. DS: Dye swap. 
  
Chromosome Cytoband Gene Start End Probes 
Log2ratio_Dir
ect 
Log2rat
io_ DS 
Pools 
4 q34.1 GALNTL6 173661791 173666272 8 -1.00 1.20 FM_3 
7 q36.3 WDR60 158400565 158402804 9 0.48 -0.32 FM_3 
8 p21.2 DOCK5 25122432 25126488 6 -1.58 1.21 FM_2 
9 p23 PTPRD 10394403 10395130 3 -2.22 1.83 FM_2 
14 q31.1 NRXN3 79175885 79184422 18 -0.54 0.58 FM_3 
16 q23.1 WWOX 76929398 76941774 11 -0.46 0.54 FM_3 
20 p13 SIRPB1 1511432 1531941 28 -0.41 0.47 FM_2 
 SUPPLEMENTARY FIGURES LEGENDS:  
Supplementary figure 1: Workflow indicating which sample sets were used in each analysis. 
Supplementary figure 2: Power calculation graph. For each OR, the given power for three 
different minor allele frequency variants is calculated (given our sample size). OR are 
represented in the X axis, and power is represented in the Y axis.   
Supplementary figure 3:  SNTG2 expression levels (as assessed by one probe) for the three 
rs11127292 genotypes  in twins’ lymphoblastyoid cell lines (GENVAR software).  
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